NCCN Guidelines® Insights - Bladder Cancer, Version 2.2022

NCCN Guidelines® Insights - Bladder Cancer, Version 2.2022 is organized by National Comprehensive Cancer Network (NCCN).,Description:,The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, and primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle-invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.,Learning Objectives:,Upon completion of this activity, participants will be able to:,• Integrate into professional practice the updates to the NCCN Guidelines for Bladder Cancer,• Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Bladder Cancer,Additional details will be posted as soon as information is available.